Anna V Tinker Selected Research

Ovarian Neoplasms (Ovarian Cancer)

1/2023	Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer.
1/2023	Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
1/2022	A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.
1/2022	Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.
12/2021	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
12/2021	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib.
1/2021	Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
1/2021	Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
1/2021	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
2/2020	Omission of adjuvant therapy in stage I clear cell ovarian cancer: Review of the BC Cancer experience.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anna V Tinker Research Topics

Disease

36	Neoplasms (Cancer) 01/2024 - 01/2008
22	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 02/2009
19	Carcinoma (Carcinomatosis) 01/2023 - 02/2009
7	Endometrial Neoplasms (Endometrial Cancer) 11/2023 - 01/2008
6	Ovarian Epithelial Carcinoma 01/2023 - 01/2017
5	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2024 - 01/2013
5	Disease Progression 11/2023 - 01/2017
3	Microsatellite Instability 01/2023 - 10/2021
3	Neutropenia 01/2021 - 12/2016
3	Fatigue 01/2021 - 11/2017
3	Breast Neoplasms (Breast Cancer) 01/2019 - 11/2017
2	Adenocarcinoma 01/2024 - 12/2018
2	Turcot syndrome 11/2023 - 01/2022
2	Hypoxia (Hypoxemia) 01/2023 - 01/2017
2	Fallopian Tube Neoplasms 12/2021 - 10/2012
2	Asthenia 01/2021 - 11/2017
2	Thrombocytopenia (Thrombopenia) 01/2018 - 12/2016
2	Nausea 01/2018 - 11/2017
2	Anemia 11/2017 - 12/2016
1	Embolism (Embolus) 01/2024
1	Dyspnea (Shortness of Breath) 01/2024
1	Diarrhea 01/2024
1	Arthralgia (Joint Pain) 11/2023
1	Hypothyroidism 11/2023
1	Drug-Related Side Effects and Adverse Reactions 01/2022
1	Endometriosis 01/2022
1	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 01/2022
1	Phototoxic Dermatitis (Phototoxicity) 01/2022
1	Cicatrix (Scar) 01/2021
1	Exanthema (Rash) 01/2021
1	Intestinal Obstruction (Obstruction, Intestinal) 01/2021
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021
1	Sepsis (Septicemia) 01/2021
1	Stomatitis 01/2021
1	Lymphatic Metastasis 02/2020
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2018
1	Vomiting 11/2017
1	Mucinous Adenocarcinoma (Mucinous Carcinoma) 11/2017
1	Rupture 11/2017
1	Gestational Trophoblastic Disease (Trophoblastic Neoplasms, Gestational) 11/2017

Drug/Important Bio-Agent (IBA)

21	PlatinumIBA 01/2024 - 02/2009
13	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023 - 01/2012
8	Biomarkers (Surrogate Marker)IBA 11/2023 - 10/2012
8	rucaparibIBA 12/2021 - 01/2017
6	dostarlimabIBA 11/2023 - 11/2020
4	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2023 - 12/2016
4	DNA (Deoxyribonucleic Acid)IBA 11/2017 - 02/2009
3	Immune Checkpoint InhibitorsIBA 11/2023 - 01/2021
3	niraparibIBA 01/2019 - 12/2016
3	Proteins (Proteins, Gene)FDA Link 01/2019 - 02/2009
2	Tyrosine Kinase InhibitorsIBA 01/2024 - 01/2023
2	Alanine Transaminase (SGPT)IBA 11/2023 - 01/2021
2	pembrolizumabIBA 01/2023 - 01/2021
2	Monoclonal AntibodiesIBA 10/2021 - 11/2020
2	ParaffinIBA 01/2021 - 12/2014
2	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 01/2008
2	Formaldehyde (Formol)FDA Link 01/2021 - 12/2014
2	Hemoglobins (Hemoglobin)IBA 01/2021 - 11/2017
1	neratinibIBA 01/2024
1	Tumor Biomarkers (Tumor Markers)IBA 11/2023
1	adavosertibIBA 07/2023
1	lenvatinibIBA 01/2023
1	Taxoids (Taxanes)IBA 01/2023
1	AnthracyclinesIBA 01/2023
1	B7-H1 AntigenIBA 01/2023
1	Carbonic Anhydrase IXIBA 01/2023
1	Indicators and Reagents (Reagents)IBA 01/2023
1	EnzymesIBA 01/2023
1	olaparibIBA 10/2022
1	ChromatinIBA 01/2022
1	CX 5461IBA 01/2022
1	Poly Adenosine Diphosphate RiboseIBA 12/2021
1	1-dodecylpyridoxal (PLD)IBA 01/2021
1	liposomal doxorubicin (Doxil)FDA Link 01/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021
1	CreatinineIBA 01/2021
1	LigandsIBA 01/2021
1	NucleotidesIBA 01/2021
1	avelumabIBA 01/2021
1	monalizumabIBA 10/2019
1	Circulating Tumor DNAIBA 01/2019
1	Cell-Free Nucleic AcidsIBA 01/2019
1	IpilimumabIBA 12/2018
1	Bevacizumab (Avastin)FDA Link 10/2018
1	Small Interfering RNA (siRNA)IBA 01/2017
1	Lys01IBA 01/2017
1	Sunitinib (Sutent)FDA Link 01/2017
1	Adenosine Diphosphate Ribose (ADP-Ribose)IBA 12/2016
1	Adenosine Diphosphate (ADP)IBA 12/2016
1	Membrane Proteins (Integral Membrane Proteins)IBA 02/2016

Therapy/Procedure

20	Therapeutics 01/2024 - 01/2008
18	Drug Therapy (Chemotherapy) 01/2024 - 06/2014
3	Radiotherapy 01/2022 - 01/2013
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2022
1	Aftercare (After-Treatment) 10/2021
1	Precision Medicine 10/2020
1	Lymph Node Excision (Lymph Node Dissection) 02/2020
1	Immunotherapy 12/2018
1	Adjuvant Radiotherapy 11/2017
1	Neoadjuvant Therapy 08/2015